Libtayo® (cemiplimab) in combination with chemotherapy approved by european commission for the first-line treatment of advanced pd-l1 positive non-small cell lung cancer (nsclc)

Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in phase 3 trial designed to include patients with varied disease presentations seen in everyday clinical practice

REGN Ratings Summary

REGN Quant Ranking